Published in Cardiovasc Res on March 01, 2002
Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg (2012) 1.49
Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J (2003) 1.40
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation (2006) 1.38
RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes (2008) 1.18
The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev (2004) 1.17
Mechanisms of sex differences in TNFR2-mediated cardioprotection. Circulation (2008) 1.13
Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol (2011) 1.11
Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes (2013) 1.05
Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts. Cell Biochem Biophys (2014) 0.98
Peripartum cardiomyopathy: review of the literature. Yonsei Med J (2007) 0.98
Compartmentation of membrane processes and nucleotide dynamics in diffusion-restricted cardiac cell microenvironment. J Mol Cell Cardiol (2011) 0.93
Peripartum Cardiomyopathy: Current Therapeutic Perspectives. Curr Treat Options Cardiovasc Med (2004) 0.91
Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure. J Transl Med (2011) 0.90
Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol (2015) 0.88
The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int (2006) 0.85
Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome. J Am Heart Assoc (2014) 0.84
Acute heart failure: patient characteristics and pathophysiology. Curr Heart Fail Rep (2013) 0.80
Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials (2015) 0.80
Pro/Anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling. Mediators Inflamm (2010) 0.80
p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity. Toxicol Appl Pharmacol (2011) 0.77
Circulating annexin A5 levels after atrial switch for transposition of the great arteries: relationship with ventricular deformation and geometry. PLoS One (2012) 0.77
MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.76
Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin (2012) 0.76
Effects of a novel bradykinin B1 receptor antagonist and angiotensin II receptor blockade on experimental myocardial infarction in rats. PLoS One (2012) 0.76
Tissue-Engineering for the Study of Cardiac Biomechanics. J Biomech Eng (2016) 0.76
Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr Diabetes (2016) 0.76
An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model. Korean J Pediatr (2013) 0.75
Increased expression of 78 kD glucose-regulated protein promotes cardiomyocyte apoptosis in a rat model of liver cirrhosis. Int J Clin Exp Pathol (2015) 0.75
Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Exp Ther Med (2015) 0.75
Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci (2017) 0.75
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2012) 2.78
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2014) 2.58
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol (2012) 2.56
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
Sex differences in medical care and early death after acute myocardial infarction. Circulation (2008) 2.17
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol (2009) 2.08
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg (2011) 1.88
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail (2010) 1.82
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res (2004) 1.68
Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol (2002) 1.68
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg (2007) 1.57
Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci (2008) 1.53
Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg (2011) 1.50
Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol (2005) 1.47
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
A prospective, randomized study of endothelin and postoperative recovery in off-pump versus conventional coronary artery bypass surgery. J Cardiothorac Vasc Anesth (2004) 1.46
Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2002) 1.45
The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol (2007) 1.45
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail (2012) 1.43
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg (2007) 1.42
Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab (2005) 1.42
Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mol Cell Cardiol (2003) 1.42
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res (2008) 1.42
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation (2003) 1.40
Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg (2003) 1.39
Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. Am J Cardiol (2010) 1.38
Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation (2006) 1.32
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res (2007) 1.32
Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res (2006) 1.29
Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation (2011) 1.24
Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation (2009) 1.23
Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg (2008) 1.23
Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol (2012) 1.21
Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet (2011) 1.20
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail (2011) 1.19
TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol (2002) 1.17
Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation (2004) 1.16
Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail (2007) 1.16
A murine model of thoracic aortic aneurysms. J Surg Res (2003) 1.16
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol (2003) 1.15
Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) (2009) 1.14
Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg (2003) 1.13
Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail (2012) 1.13
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation (2005) 1.11
Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail (2011) 1.10
Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med (2014) 1.08
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. Am J Surg (2008) 1.07
Analyzing Propensity Matched Zero-Inflated Count Outcomes in Observational Studies. J Appl Stat (2014) 1.07
Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet (2011) 1.06
Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev (2005) 1.06
Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg (2011) 1.06
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol (2012) 1.06
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol (2005) 1.05
Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging (2011) 1.04
Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation. Ann Thorac Surg (2008) 1.03
Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation (2009) 1.03
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol (2006) 1.02
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail (2002) 1.01
Barriers to non-HDL cholesterol goal attainment by providers. Am J Med (2011) 1.01